E. Gautherot

发表

NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML

D. Olive, D. Blaise, A. Toubert, 2017, Oncoimmunology.

Major Histocompatibility Complex Class II Molecule-Human Immunodeficiency Virus Peptide Analysis Using a Microarray Chip

Marie Reilly, Shahnaz Mahdavifar, Johannes Zerweck, 2009, Clinical and Vaccine Immunology.

ENHANCED IN VIVO TARGETING OF AN ASYMMETRIC BIVALENT HAPTEN ANTIBODY CONJUGATE COCKTAILS TO DOUBLE-ANTIGEN-POSITIVE MOUSE B CELLS WITH MONOCLONAL

E. Gautherot, J. Barbet, J. L. Doussal, 1991 .

Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies.

B. Klein, E. Gautherot, F. Montero-Julian, 1995, Blood.

Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.

E. Gautherot, J. Barbet, E. Rouvier, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate.

E. Gautherot, J. Barbet, M. Delaage, 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.

F. Kraeber-Bodéré, E. Gautherot, M. Fiche, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody.

F. Kraeber-Bodéré, E. Gautherot, M. Fiche, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.

F. Kraeber-Bodéré, E. Gautherot, M. Fiche, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice.

E. Gautherot, J. Barbet, A. Gruaz-Guyon, 1990, Cancer research.

Rhenium-188-labeled anti-neural cell adhesion molecule antibodies with 2-iminothiolane modification for targeting small-cell lung cancer

E. Gautherot, A. Mishra, J. Chatal, 2000, Annals of nuclear medicine.

Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response.

E. Gautherot, J. Chatal, J. Barbet, 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies.

E. Gautherot, J. Chatal, J. Barbet, 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy.

E. Gautherot, W. Rostène, J. Barbet, 1997, Bioconjugate chemistry.

Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten.

F. Kraeber-Bodéré, E. Gautherot, J. Chatal, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Pharmacokinetics of interleukin-6 during therapy with anti-interleukin-6 monoclonal antibodies: enhanced clearance of interleukin-6 by a combination of three anti-interleukin-6 antibodies.

B. Klein, E. Gautherot, J. Wijdenes, 1994, Journal of interferon research.

Bifunctional antibodies for radioimmunotherapy.

E. Gautherot, J. Chatal, J. Barbet, 1995, Hybridoma.

Bispecffic Monoclonal Antibody-Mediated Targeting of an Indium-ill-Labeled DTPA Dimer to Primary Colorectal Tumors: Pharmacokinetics , Biodistribution, Scintigraphy and Immune Response

E. Gautherot, J. Barbet, A. Gruaz-Guyon, 2006 .

Enhanced in vivo targeting of an asymmetric bivalent hapten to double-antigen-positive mouse B cells with monoclonal antibody conjugate cocktails.

E. Gautherot, J. Barbet, M. Delaage, 1991, Journal of immunology.

Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.

F. Kraeber-Bodéré, E. Gautherot, M. Fiche, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

The new violet laser dye, Krome Orange, allows an optimal polychromatic immunophenotyping based on CD45-KO gating.

E. Gautherot, E. Huys, F. Preijers, 2011, Journal of immunological methods.

A nude mice model of human rhabdomyosarcoma lung metastases for evaluating the role of polysialic acids in the metastatic process

D. Figarella-Branger, G. Rougon, E. Gautherot, 2001, Oncogene.

Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia

S. Granjeaud, D. Olive, A. Toubert, 2017, Front. Immunol..

Comparative targeting of human colon‐carcinoma multicell spheroids using one‐ and two‐step (bispecific antibody) techniques

E. Gautherot, J. Chatal, J. Barbet, 1996, International journal of cancer.

Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial.

J. Douillard, P. Moreau, D. Moro, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial.

M Bardiès, F. Kraeber-Bodéré, S. Bardet, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pretargeting with the affinity enhancement system for radioimmunotherapy.

F. Kraeber-Bodéré, E. Gautherot, J. Chatal, 1999, Cancer biotherapy & radiopharmaceuticals.

Targeting medullary thyroid carcinomas with bispecific antibodies and bivalent haptens. Results and clinical perspectives.

E. Gautherot, J. Barbet, E. Rouvier, 1997, Hormone research.

Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer.

M Bardiès, A Lisbona, J. Douillard, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.

E. Gautherot, J. Barbet, E. Rouvier, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia

S. Granjeaud, D. Olive, A. Cerwenka, 2017, Oncotarget.

Therapy for colon carcinoma xenografts with bispecific antibody‐targeted, iodine‐131‐labeled bivalent hapten

E. Gautherot, J. Barbet, E. Rouvier, 1997, Cancer.

Pretargeted radioimmunotherapy using131I-labelled bivalent hapten-bearing peptides

E. Gautherot, W. Rostène, J. Barbet, 1997, Letters in Peptide Science.

Pretargeted radioimmunotherapy using 131I-labelled bivalent hapten-bearing peptides

E. Gautherot, W. Rostène, J. Barbet, 2004, Letters in Peptide Science.

Targeting BCL1 lymphoma with anti‐idiotype antibodies: Biodistribution kinetics of directly labeled antibodies and bispecific antibody‐targeted bivalent haptens

E. Gautherot, J. Barbet, E. Rouvier, 1997, International journal of cancer.